Cadrenal Therapeutics (CVKD) Earnings Date & Reports
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
CVKD is expected to report earnings to fall 25.67% to -138 cents per share on November 06
Q3'25
Est.
$-1.39
Q2'25
Missed
by $0.61
Q4'24
Missed
by $1.88
Q3'24
Missed
by $2.06
Q2'24
Missed
by $2.13
The last earnings report on August 11 showed earnings per share of -187 cents, missing the estimate of -125 cents. With 13.96K shares outstanding, the current market capitalization sits at 25.54M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CVKD showed earnings on August 11, 2025. You can read more about the earnings report here.